Archives of Medical Research
Volume 37, Issue 6 , Pages 744-748 , August 2006

Influence of Skin Color on the Diagnostic Utility of Clinical Acanthosis Nigricans to Predict Insulin Resistance in Obese Patients

  • Juan Carlos Lopez-Alvarenga

      Affiliations

    • Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas
    • Department of Endocrinology, Instituto Nacional de Ciencias Médicas Salvador Zubiran, Mexico City, Mexico
    • Corresponding Author InformationAddress reprint requests to: Juan Carlos Lopez-Alvarenga, Southwest Foundation for Biomedical Research, P.O. Box 760549, San Antonio, TX 78245
    • ,
  • Linda García-Hidalgo

      Affiliations

    • Department of Dermatology, Instituto Nacional de Ciencias Médicas Salvador Zubiran, Mexico City, Mexico
    • ,
  • María Victoria Landa-Anell

      Affiliations

    • Department of Endocrinology, Instituto Nacional de Ciencias Médicas Salvador Zubiran, Mexico City, Mexico
    • ,
  • Rosario Santos-Gómez

      Affiliations

    • Department of Endocrinology, Instituto Nacional de Ciencias Médicas Salvador Zubiran, Mexico City, Mexico
    • ,
  • Jorge González-Barranco

      Affiliations

    • División de Investigación del Hospital Federico Gomez, Mexico City, Mexico
    • ,
  • Anthony Comuzzie

      Affiliations

    • Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas

Received 6 June 2005 ,Accepted 20 December 2005.

References 

  1. Kuner N, Hartschuh W. First descriptions in the “International Atlas of Rare Skin Diseases” of 1886. Hautarzt. 2003;54:67–72
  2. Wilgenbus K, Lentner A, Kuckelkorn R, Handt S, Mittermayer C. Further evidence that acanthosis nigricans maligna is linked to enhanced secretion by the tumour of transforming growth factor alpha. Arch Dermatol Res. 1992;284:266–270
  3. Levin N. Acanthosis nigricans. eMedicine J: 2002 June 14. Available at: http://author.emedicine.com/CGI-BIN/FOXWEB.EXE/WORKONPREP@c:/em/ga?book=derm
  4. Litonjua P, Pinero-Pilona A, Aviles-Santa L, Raskin P. Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract. 2004;10:101–106
  5. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med. 1995;99:420–426
  6. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–745
  7. Khan BB, Flier J. Obesity and insulin resistance. J Clin Invest. 2000;106:473–482
  8. Accili D. The struggle for mastery in insulin action: from triumvirate to republic. Diabetes. 2004;53:1633–1642
  9. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147:1096–1101
  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  11. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, et al. Critical evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27:978–983
  12. Burke JP, Duggirala R, Hale DE, Blangero J, Stern MP. Genetic basis of acanthosis nigricans in Mexican Americans and its association with phenotypes related to type 2 diabetes. Hum Genet. 2000;106:467–472
  13. Kerem N, Guttman H, Hochberg Z. The autosomal dominant trait of obesity, acanthosis nigricans, hypertension, ischemic heart disease and diabetes type 2. Hormone Res. 2001;55:298–304
  14. Schiavon R, Altamirano-Bustamante N, Jimenez C, Calzada-Leon R, Robles-Valdes C, Larrea F. Fasting and postprandial serum insulin in Mexican adolescents with menstrual disorders. Rev Invest Clin. 1996;48:335–342
  15. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med. 1989;87:269–272
  16. Araujo LM, Porto MV, Netto EM, Ursich MJ. Association of acanthosis nigricans with race and metabolic disturbances in obese women. Braz J Med Biol Res. 2002;35:59–64
  17. Hirschler V, Aranda C, Oneto A, Gonzalez C, Jadzinsky M. Is acanthosis nigricans a marker of insulin resistance in obese children?. Diabetes Care. 2002;25:2353
  18. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(Suppl 1):S5–S10
  19. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale for acanthosis nigricans. Diabetes Care. 1999;22:1655–1659
  20. Astner S, Anderson RR. Skin phototypes 2003. J Investig Dermatol. 2004;122:xxx–xxxi
  21. Landis JR, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  22. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care. 1999;22:1462–1470
  23. Stuart CA, Smith MM, Gilkison CR, Shaheb S, Stahn RM. Acanthosis nigricans among Native Americans: an indicator of high diabetes risk. Am J Public Health. 1994;84:1839–1842
  24. Lievens P, Mutinelli C, Baynes D, Liboi E. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biochem Chem. 2004;279:43254–43260
  25. Flier JS, Usher P, Mosses AC. Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci USA. 1986;83:664–668
  26. Alberti FGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998;15:539–553

PII: S0188-4409(06)00091-9

doi: 10.1016/j.arcmed.2005.12.007

Archives of Medical Research
Volume 37, Issue 6 , Pages 744-748 , August 2006

Article Tools

* Image Usage & Resolution